Progranulin, a secreted glycoprotein, is encoded in humans by the single GRN gene. Progranulin consists of seven and a half, tandemly repeated, non-identical copies of the 12 cysteine granulin motif. Many cellular processes and diseases are associated with this unique pleiotropic factor that include, but are not limited to, embryogenesis, tumorigenesis, inflammation, wound repair, neurodegeneration and lysosome function. Haploinsufficiency caused by autosomal dominant mutations within the GRN gene leads to frontotemporal lobar degeneration, a progressive neuronal atrophy that presents in patients as frontotemporal dementia. Frontotemporal dementia is an early onset form of dementia, distinct from Alzheimer's disease. The GRN-related form of frontotemporal lobar dementia is a proteinopathy characterized by the appearance of neuronal inclusions containing ubiquitinated and fragmented TDP-43 (encoded by TARDBP). The neurotrophic and neuro-immunomodulatory properties of progranulin have recently been reported but are still not well understood. Gene delivery of GRN in experimental models of Alzheimer's-and Parkinson's-like diseases inhibits phenotype progression. Here we review what is currently known concerning the molecular function and mechanism of action of progranulin in normal physiological and pathophysiological conditions in both in vitro and in vivo models. The potential therapeutic applications of progranulin in treating neurodegenerative diseases are highlighted.
Introduction
With the ageing human population, neurodegenerative disease has become a growing and currently intractable health challenge (Finès, 2015) . Progranulin, a secreted glycoprotein, maintains cerebrocortical viability. It has been identified as an important factor controlling neural function while also suppressing neuroinflammation and playing roles in neuronal lysosome function (Toh et al., 2011) . Loss of one allele of GRN, the gene encoding progranulin, leads to the development of frontotemporal dementia (FTD) Cruts et al., 2006) . This is the second most common form of dementia in people under the age of 65 (Arvanitakis, 2010) . Loss of both alleles leads to the development of neuronal ceroid lipofuscinosis (NCL) (Smith et al., 2012) , a lysosome storage disease. Importantly, in addition to its link to the development of frontotemporal lobar degeneration (FTLD), progranulin is protective in a range of animal models with disrupted neuronal growth and developmental processes. For example, progranulin overexpression reverses the impaired development of primary motor neurons in zebrafish models of motor neuron disease including spinal muscular atrophy caused by reduced expression of survival motor neuron 1 (smn1) (Chitramuthu et al., 2010) and amyotrophic lateral sclerosis (ALS) (Laird et al., 2010) due to exogenous expression of mutant TAR DNA binding protein-43 (TDP43). Progranulin has a neuroprotective role in a Caenorhabditis elegans model of Huntington's disease and in immortalized striatal neurons carrying pathological variations of the polyglutamine expansion of the huntingtin protein (Tauffenberger et al., 2013) . In mice, the lentiviral delivery of Grn to the brain halts the development of drug-induced Parkinson's-like phenotypes (Van Kampen et al., 2014) and genetically-induced Alzheimer's disease-like phenotypes (Minami et al., 2014) . These observations indicate that progranulin has a broad spectrum of potential therapeutic utility in several presently incurable neurological disorders including both those with or without associated TDP-43 proteinopathy. To exploit this potential, we must fully understand the mode of action of progranulin. This review focuses on the roles of progranulin in the CNS and neuronal diseases.
Progranulin structural organization and processing
Progranulin (Fig. 1) is the sole mammalian representative of a gene family the evolutionary origins of which can be traced to single celled organisms (Palfree et al., 2015) . Human progranulin is a glycoprotein of $75-80 kDa that contains seven and a half granulin modules namely p (a granulin half domain), G, F, B, A, C, D, and E Plowman et al., 1992) (Fig. 1 ). Solution nuclear magnetic resonance analysis of granulin-1 isolated from the spleen of a teleost fish the carp (Hrabal et al., 1996) , and individual human granulin modules (Tolkatchev et al., 2008) revealed a unique conformation for the granulin motif as a parallel stack of beta-hairpins in the form of a left-handed helix held together with six disulphide bridges (Hrabal et al., 1996; Tolkatchev et al., 2008) . Progranulin can be subject to protease cleavages that release individual granulin modules in the form of polypeptides of $6 kDa called granulins (Bateman et al., 1990) , sometimes also known as epithelins (Shoyab et al., 1990) .
Both intact progranulin and its constituent granulin peptides are biologically active although often with opposing actions. For example, progranulin plays anti-inflammatory roles (Zhu et al., 2002; Jian et al., 2013) whereas granulin peptides have pro-inflammatory functions (Zhu et al., 2002; Jian et al., 2013) . With respect to cell growth, intact progranulin is mitogenic whereas the different granulin polypeptides may have growth promoting or growth inhibiting activities on, for example, breast cancer cells, although they usually act with lower potency than intact progranulin. In the periphery, neutrophil proteases including elastases and proteinase-3 cleave progranulin into individual granulin peptides (Zhu et al., 2002) . The balance between undigested progranulin and its proteolytically derived granulin peptides is controlled at least in part by the secretory leucocyte protease inhibitor (SLPI) (Zhu et al., 2002) , which binds to progranulin, thereby preventing proteolysis by elastase and other neutrophil proteases (Fig. 1) . The functional interplay between progranulin and proteases Figure 1 Diagrammatic representation of the human GRN gene, progranulin protein and its proteolytic digestion pathway to granulin peptides. (Top) The exonic structure of the GRN gene (dark blue for UTRs). (Middle) The protein structure with lettered boxes that represent individual granulin modules. The thin lines descending from the gene structure indicate which exons contribute to which protein modules . SLPI binds at sequences between granulin modules to protect full length progranulin from proteolysis by elastase and other proteases. Intact progranulin blunts the inflammatory reaction and has growth factor-like activity. SLPI therefore promotes the anti-inflammatory and growth factor properties of progranulin. The bottom panel illustrates the cleavage of progranulin into granulin peptides some of which have proinflammatory and anti-proliferative activities (Zhu et al., 2002) .
has been confirmed in a study of compound murine knockouts of neutrophil elastase (Elane) and proteinase-3 (Prtn3) (Kessenbrock et al., 2008) . This concept is further strengthened by a prior study showing increased inflammation in mice lacking Slpi (Ashcroft et al., 2000) .
Progranulin expression and function in the healthy brain GRN mRNA expression has been reported in the developing CNS and peripheral nervous system (dorsal root ganglia and sympathetic ganglia) (Daniel et al., 2003) although another study found little evidence of early CNS Grn expression in neuronal progenitors (Petkau et al., 2010) . In the adult mouse, progranulin is found in specific neurons in Purkinje cells, pyramidal cells of the hippocampus, and some cerebral cortical neurons, motor neurons in the brain and spinal cord and in microglia (Daniel et al., 2000; Moisse et al., 2009; Ryan et al., 2009; Petkau et al., 2010; De Muynck and Van Damme, 2011) as well as neural stem cells (Lu et al., 2013) .
In vitro studies have implicated progranulin in normal neuron biology. It promotes neurite extension (Van Damme et al., 2008; Ryan et al., 2009; Gao et al., 2010; Gass et al., 2012) , neuronal cell survival (Van Damme et al., 2008; Ryan et al., 2009; Gao et al., 2010; Guo et al., 2010; Kleinberger et al., 2010; Xu et al., 2011) and differentiation Raitano et al., 2015) . The major research focus has been on progranulin and its neuropathology. In contrast, its physiological roles in the brain and nervous system are not well understood. Progranulin reduces neuropathic pain (Lim et al., 2012; Altmann et al., 2016a) and stimulates regrowth following nerve injury (Altmann et al., 2016b) . It is a developmentally regulated sex steroid-responsive factor involved in masculinization of the hypothalamus (Suzuki et al., 2009) and it may regulate hypothalamic control of feeding behaviour (Kim et al., 2011) .
Progranulin in brain diseases
Progranulin has many roles in brain diseases either through loss of one GRN allele (FTLD), both allelles (NCL) or, when overexpressed, by contributing to the development of brain tumours (Fig. 2 ).
GRN and frontotemporal lobar degeneration clinical pathology
A detailed review of clinical and diagnostic features of GRN-related FTD can be found elsewhere (Hsiung and Feldman, 2013) . FTLD is a general term used for a group of disorders that are clinically, pathologically and genetically heterogeneous, and is characterized by the degeneration of the frontal and temporal lobes, areas that control planning, judgement, emotion, speech and some types of movement. About 15-22 in 100 000 people are estimated to suffer from FTLD with no apparent differences in disease incidence reported between males and females (Onyike and Diehl-Schmid, 2013) . It often has a relatively early onset, around age 45 to 65 years (Onyike and DiehlSchmid, 2013) . The clinical pathology of FTLD includes: (i) behavioural variant FTD (bvFTD) characterized by progressive decline in behaviour and executive function; (ii) progressive non-fluent aphasia (PNFA) characterized by deficits in expressive and motor speech; and (iii) semantic dementia (Stagi et al., 2014) characterized by loss of semantic memory (reviewed in Premi et al., 2012) . Patients with FTD sometimes develop clinical signs that overlap with motor neuron disease/amyotrophic lateral sclerosis (FTD-ALS), progressive supranuclear palsy and corticobasal syndrome (CBS) associated with Parkinson's disease while 50% of patients with ALS show cognitive deficits (Lomen-Hoerth et al., 2002; Seltman and Matthews, 2012) . GRN mutations are generally associated with bvFTD, PNFA and CBS but not semantic dementia or FTD-ALS (Le Ber et al., 2007; Schymick et al., 2007; Whitwell et al., 2007; Del Bo et al., 2011) . Given that GRN mutations result in decreased production of progranulin, its measurement in serum or CSF has proven a very reliable biomarker to distinguish between FTLD caused by GRN mutation and other FTLDs and can discern whether an at-risk family member is likely to carry a GRN mutation long before any clinical symptoms may appear (Ghidoni et al., 2008; Carecchio et al., 2009; Finch et al., 2009; Sleegers et al., 2009; Schofield et al., 2010; Almeida et al., 2014) .
About 30-50% of FTLD cases are heritable (Onyike and Diehl-Schmid, 2013) with most cases being due to mutations within the three genes GRN, MAPT (microtubuleassociated protein tau), and a GGGGCC hexanucleotide repeat expansion in C9orf72 (chromosome 9 open reading frame 72) (reviewed in Sieben et al., 2012) . In addition, FTD is less commonly associated with mutations in TARDBP (TAR DNA binding protein, encoding TDP-43) (Borroni et al., 2009; Caroppo et al., 2016) , FUS (fused in sarcoma) , CHMP2B (charged multivesicular body protein 2B) (Skibinski et al., 2005; Holm et al., 2007) , VCP (valosin containing protein) (Watts et al., 2004) , SQSTM1 (sequestome 1/p62) (Le Ber et al., 2013; Kovacs et al., 2016) , UBQLN2 (ubiquilin 2) (Deng et al., 2011; Vengoechea et al., 2013) , TBK1 (TANK binding kinase 1) and OPTN (optineurin) (Pottier et al., 2015) . Unlike GRN, C9orf72 and UBQLN2 are often associated with FTLD and ALS while most mutations of TARDBP, FUS, TBK1 and OPTN are associated with ALS and only rarely with pure FTLD (Morris et al., 2012) .
Frequencies of GRN mutations in FTD cohorts in different parts of the world vary significantly. For example, the frequency of GRN mutations in Italy was 15.6%, in Japan it was 1.6% and in Brazil was 9.6% (Benussi et al., 2010; Ogaki et al., 2013; Takada et al., 2016) . C9ORF72 hexanucleotide repeat expansion is the most common underlying genetic cause in patients with ALS or FTD with or without ALS (Cruts et al., 2015; Rohrer et al., 2015a) .
Neuroimaging and neuropathology of GRN-related frontotemporal dementia
Over and above the extensive loss of frontotemporal tissue, each of the major FTLD genes results in distinct patterns of brain atrophy as revealed by neuroimaging studies, with GRN mutations often resulting in a more temporo-parietal atrophy than that resulting from MAPT or C9orf72 mutations (Whitwell et al., 2009 (Whitwell et al., , 2012 Rohrer et al., 2010) . Atrophy due to GRN mutations, but not MAPT or C9orf72, is typically asymmetric (Ghetti et al., 2008; Whitwell et al., 2013) with both left and right asymmetry observed even in the same family (Beck et al., 2008) . The underlying cause for this asymmetry is unclear. Comparing the effects of GRN, MAPT and C9orf72 mutations by longitudinal MRI of symptomatic individuals revealed that whole brain and regional rates of volume loss were most rapid in patents with GRN mutations (Whitwell et al., 2015) . In presymptomatic individuals GRN mutation carriers showed structural differences first in the insula 15 years before expected clinical onset. There follows a further period until 5 years before the expected clinical onset, during which atrophy develops in the temporal and parietal lobes and then in the striatum (Rohrer et al., 2015b) . Regional hypometabolism and decreased cerebral blood flow also occur early and before major structural changes or clinical symptoms are detectable (Jacova et al., 2013; Caroppo et al., 2015; Dopper et al., 2016) . Changes in white matter tracts and functional connectivity predate the onset of clinical symptoms in some instances by more than 10 years. (Borroni et al., 2008; Pievani et al., 2014; Premi et al., 2014) . Brains from GRN-related FTD often show greater white matter lesions than other forms of FTD (Caroppo et al., 2014) . Functional imaging in patients with GRN-related FTD show a significant decrease in connectivity between the parietal lobe and temporal pole region whereas in FTD without GRN mutations changes in functional connectivity have a more frontal orientation (Premi et al., 2013) . The specific loss of connectivity pathways in GRN-related FTD is accompanied by potentially compensatory increases in connectivity of other pathways Premi et al., 2013) . The ability to detect structural changes in grey and white matter, decreases in blood flow, and functional changes in connectivity in the brains of GRN mutation carriers years before the onset of clinical symptoms makes imaging strategies very useful as biomarkers to follow both disease progression and to monitor response to novel disease-modifying therapies during clinical trials.
Spontaneous and inherited FTLDs are characterized by the presence of cellular inclusions. Most of these are of either tau protein (FTLD-tau), associated in familial FTLD with MAPT mutations, or ubiquitinated fragments of TDP-43 (FTLD-TDP) associated with GRN and C9orf72 mutations. In FTLD-FUS inclusions occur containing FET proteins [FET stands for the RNA-binding proteins FUS, Ewing's sarcoma (EWS) and TATA-box binding protein associated factor 15 (TAF15)]. In neuronal intermediate filament inclusion disease, a subset of FTLD-FUS, (Cairns et al., 2004) inclusions of type IV neuronal intermediate filament also occur (Mackenzie and Neumann, 2016) (Fig. 3) . TDP-43 pathology is found in other neurodegenerative diseases including ALS (Arai et al., 2006; Neumann et al., 2006) and sometimes Alzheimer's disease (Wilson et al., 2011) . Four subcategories of FTLD-TDP, types A-D, are recognized on the basis of neuropathology . GRN mutations result in FTLD-TDP type A, characterized by short dystrophic neurites, ubiquitin-positive-neuronal cytoplasmic inclusions concentrated in neocortical layer 2 and often though less abundantly lentiform neuronal intranuclear inclusions (NII) in regions that include the neocortex and striatum Josephs et al., 2007; Armstrong and Cairns, 2011; Armstrong, 2014) . Mutation of VCP causes extensive NII formation (Forman et al., 2006) and it has been suggested that a convergent neuropathology, possibly centred on the proteasomal clearance of proteins that generates the NIIs in response to both GRN and VCP mutations . Representative micrographs of TDP-43 inclusions in GRN-related FTD can be found in Mackenzie et al. (2006) and Mackenzie and Neumann (2016) .
Genetics of GRN-related frontotemporal dementia
Known GRN mutations are collated in www.molgen.ua.ac. be/FTDmutations/. In most cases GRN-related FTD is caused by mutation of a single allele of GRN resulting in a premature stop codon that triggers nonsense-mediated decay of GRN mRNA and concomitant loss of 50% of progranulin protein levels Cruts et al., 2006) . This may occur due to nonsense mutations, small insertions or deletions that result in frameshift introduction of stop codons, larger deletions or mutations of splice acceptor sites (Yu et al., 2010; Chen-Plotkin et al., 2011) . There are no obvious regional 'hot-spots' of mutation. Locus deletion mutants Rovelet-Lecrux et al., 2008) that lack all or most of the GRN gene confirm that it is indeed the loss of a single GRN allele and not the acquired toxicity of mutant progranulin proteins that causes the FTLD phenotype. Several missense mutations of GRN have been reported. These transcripts are not cleared by nonsensemediated decay but since the GRN gene tolerates a number of benign polymorphisms (Guerreiro et al., 2010) it is sometimes difficult to distinguish pathological GRN missense mutations from non-pathological variations. Missense mutations in the initiator methionine codon, or its removal by splicing out of exon 1, prevent GRN mRNA translation Cruts et al., 2006; Gass et al., 2006; Le Ber et al., 2008) . The pathogenicity of the missense mutation progranulin A9D is well documented (Mukherjee et al., 2006; Spina et al., 2007; Chen-Plotkin et al., 2011; Cannon et al., 2013) . A charged aspartic acid residue takes the place of alanine in the hydrophobic core of the signal peptide, preventing passage of progranulin through the secretory pathway (Shankaran et al., 2008; Finch et al., 2009) . As with the haploinsufficient GRN null mutations, the net effect is to reduce secreted progranulin levels by $50%. Additional factors may also contribute to the pathology of this mutation since, by mislocating to the cytoplasm (Shankaran et al., 2008) , progranulin A9D can associate with stress granules and may initiate harmful actions independently of its exclusion from the secretory pathway (Li et al., 2017) . Other missense mutations, such as progranulin P248L in granulin domain B, and R432C between granulin domains C and D, reduce progranulin secretion, but to a lesser extent than for the A9D signal peptide mutants (Shankaran et al., 2008) . Missense mutations, C139R (Brouwers et al., 2008; Bernardi et al., 2009; Wang et al., 2010a; Antonell et al., 2012; Gass et al., 2012) , in the F domain and C521Y (Wang et al., 2010a) in the E granulin domain do not alter progranulin secretion (Brouwers et al., 2008) or do so to a lesser degree than null mutations (Finch et al., 2009) . However, progranulin P248L, R432C, C139R and C521Y are all functionally impaired in the ability to stimulate neurite outgrowth in vitro (Wang et al., 2010a; Gass et al., 2012) . Their reduced functionality and, in some cases, reduced secretion may confer a milder and less penetrant phenotype than the null mutations.
Genetic risk factors for GRN-related frontotemporal dementia
There is a wide clinical heterogeneity and disparity in the age of onset of FTD even among closely related family members who carry the same GRN mutation (Bruni et al., 2007; Le Ber et al., 2007; Rademakers et al., 2007; Beck et al., 2008; Benussi et al., 2015) . This has spurred the search for genetic modifiers that might account for this variability. Genome-wide association studies identified a SNP (rs646776), linked to the gene SORT1, that influences serum levels of progranulin (Carrasquillo et al., 2010) . SORT1 encodes sortilin 1, a transmembrane protein that had been found to modulate secreted levels of progranulin through endocytosis . Sortilin is a regulator of lysosomal enzyme trafficking and binds to multiple neurotrophic factors in addition to progranulin including neurotensin, pro-NGF (Nykjaer et al., 2004) and other members of the neurotrophin family (Bartkowska et al., 2010) . Similarly, genome-wide association studies revealed that another lysosome trafficking protein, prosaposin, also regulates progranulin levels in the circulation (Nicholson et al., 2016) . Progranulin binds to prosaposin (Zhou et al., 2015b) . Single nucleotide polymorphisms (SNPs) that are associated with the gene transmembrane protein 106B (TMEM106B) were found to be risk factors for FTLD-TDP through a mechanism resulting in increased TMEM106B expression (Van Deerlin et al., 2010; Finch et al., 2011) . Importantly, the risk is highly significant for GRN-mutation carriers (Van Deerlin et al., 2010; Finch et al., 2011; van der Zee et al., 2011) . For example, the risk allelle of rs1990622 (TMEM106B) is associated with a mean decrease in the age of onset of FTD of 13 years in GRN-mutation carriers (Cruchaga et al., 2011) , and is linked to decreases in plasma progranulin levels observed both in the carriers and in healthy older adults (Van Deerlin et al., 2010; Cruchaga et al., 2011; Finch et al., 2011) . As with sortilin and prosaposin, TMEM106B may act on progranulin levels through lysosomal pathways since TMEM106B, a type 2 transmembrane glycoprotein (Lang et al., 2012) , plays a role in regulating lysosome size, motility and the stress response (Stagi et al., 2014) . Over-expression of TMEM106B in neuronal cell lines reduces lysosomal breakdown of progranulin (Brady et al., 2013) .
While the apolipoprotein E (APOE "4) allele is a major genetic risk factor in the development of Alzheimer's disease, it has the opposite effect in GRN-related FTD, delaying disease onset by a mean of $6 years Beck et al., 2008) . The biological rationale behind the different effects of APOE in Alzheimer's disease and GRN-related FTD is unclear. The actin-binding protein filamin-c is highly upregulated in the frontal cortices of FTD patients with TDP-43 inclusions especially those with GRN mutations compared to C9orf72 tract expansions and VCP mutations (Janssens et al., 2015) . The MAPT haplotype has no major effect on the age of disease onset in the case of GRNrelated FTLD Rademakers et al., 2007) . However, greater phosphorylation and intraneuronal accumulation of tau protein was noted in P301L Mapt/Grn hemizygotic mice compared to P301L Mapt mice, suggesting a possible mechanism through which progranulin levels might interact with tau pathologies in, for example, Alzheimer's disease (Hosokawa et al., 2015) .
Multiple miRNAs may contribute to the pathogenesis of FTLD due to progranulin deficiency. For example, genetic variability in a microRNA binding site near the 3' untranslated region (3'-UTR) (rs5848) of GRN, which contributes to translational inhibition may lead to reduced progranulin levels (Rademakers et al., 2008; Hsiung et al., 2011) . MiR29b and miR-107 directly regulate progranulin levels (Jiao et al., 2010; Wang et al., 2010b; Gascon and Gao, 2014) . Three members of the miR-132 cluster that are downregulated in FTD brains with TDP-43 inclusions were associated with upregulation of TMEM106B, a gene that modifies progranulin action as noted earlier (Chen-Plotkin et al., 2012) . GRN expression is, in addition, regulated epigenetically by promoter methylation. When compared to age-matched control brains, patients with sporadic FTD exhibit hypermethylation of functionally critical CpG units within the GRN promoter (BanzhafStrathmann et al., 2013; Galimberti et al., 2013) .
Taken together these observations reveal a complex network of genetic factors that act to influence progranulin protein levels or mRNA expression. Alterations in the activity of any one of these factors may influence the progression of GRN-related FTD.
Genetic variability of GRN in neurodegenerative conditions other than frontotemporal lobar degeneration
The influence of genetic variation of GRN as risk factors in a range of neurological diseases has been investigated. Some studies found either no association of GRN variants with Parkinson's disease or Alzheimer's disease or only revealed variants that are predicted to be non-pathological (Nuytemans et al., 2008; Yu et al., 2010; Karch et al., 2013) . However, other research did detect significant contribution of GRN genetic variability to Alzheimer's disease (Brouwers et al., 2007 (Brouwers et al., , 2008 Kelley et al., 2010; Perry et al., 2013; Redaelli et al., 2017) and hippocampal sclerosis (Dickson et al., 2010) . In addition, GRN variability is reported in schizophrenia (Momeni et al., 2010) , bipolar disorder (Galimberti et al., 2014) and multiple sclerosis (Fenoglio et al., 2010) , although many of these results are based on relatively small sample sizes.
Homozygous mutation of GRN and lysosome storage disease
While heterozygous mutations of GRN result in FTLD, homozygous GRN mutations lead to a different disease associated with lysosomal dysfunction, namely late onset NCL (Smith et al., 2012; Almeida et al., 2016) . NCL is a lysosomal storage disease that is caused by mutations in at least 14 different genes and is characterized by the appearance of deposits of the autofluorescent storage material lipofuscin. NCL caused by loss of progranulin is classified as NCL 11. These results strongly suggest a role for progranulin in lysosome function.
Progranulin and brain tumours
Just as a deficit in progranulin levels leads to disease, proliferative brain disorders are associated with excessive expression of progranulin. Thus, it is often highly expressed in gliomas (Liau et al., 2000) . Progranulin plays a role in astrocytoma progression and is a prognostic biomarker for glioblastoma, with its overexpression predicting decreased survival . Progranulin is overexpressed in tumours of patients with glioblastoma multiforme and is associated with tumorigenicity and temozolomide resistance (Bandey et al., 2015) . This is caused by upregulation of cancer stemness genes by progranulin (Bandey et al., 2015) . Progranulin is, moreover, implicated in the growth of intracranial meningiomas (Kim et al., 2010) . Although relatively little is known about progranulin in brain cancers, its ability to promote cancer more generally is amply confirmed by a wealth of studies demonstrating tumorigenic activity in many other types of cancer. These include carcinomas of the ovary (Jones et al., 2003; Kamrava et al., 2005; Liu et al., 2007; Cuevas-Antonio et al., 2010) , endometrium (Jones et al., 2006) , liver (Cheung et al., 2004; Ho et al., 2008) , breast (Lu and Serrero, 2001; Leerkes et al., 2002; Egland et al., 2003; Serrero and Ioffe, 2003; Tangkeangsirisin and Serrero, 2004; Elkabets et al., 2011) , kidney (Donald et al., 2001) , prostate (Monami et al., 2009) , adrenal cortex (He et al., 2002) and bladder (Monami et al., 2006) as well as non-epithelial cancers such as multiple myelomas (Wang et al., 2003) and leiomyosarcomas (Matsumura et al., 2006) . In addition to tumour growth stimulation, progranulin promotes cancer cell migration, invasiveness, anchorage independence and chemoresistance He et al., 2002; Tangkeangsirisin and Serrero, 2004; Monami et al., 2006 Monami et al., , 2009 Cheung et al., 2011) . Progranulin expression alone does not transform primary human cells. However, if the primary cells are first immortalized by co-expression of the SV40 T-antigen and telomerase, the further expression of GRN transforms them from a precancerous to a highly tumorigenic state (Matsumura et al., 2006; Miyanishi et al., 2007) . It is anticipated that a similar relationship may hold with respect to progranulin in the transition from precancerous but non-transformed cells to cancerous cells in the brain.
Progranulin and neuroinflammation
Microglial progranulin expression is upregulated after traumatic brain injury (Tanaka et al., 2013a) , toxin-induced injury (Martens et al., 2012) , spinal cord injury (Naphade et al., 2010; Byrnes et al., 2011) and sciatic axotomy (Moisse et al., 2009) suggesting roles for progranulin in the neuroinflammatory reaction to brain injury. Activated microglia with strong progranulin expression are observed in affected brain regions of GRN-related FTLD patients , in ALS (Malaspina et al., 2001; Irwin et al., 2009; Philips et al., 2010 ), Alzheimer's disease (Gliebus et al., 2009; Pereson et al., 2009) , Lewy body-associated dementia (Revuelta et al., 2008) and multiple sclerosis (Vercellino et al., 2011) . Interestingly, neuronal progranulin expression either did not change (Petkau et al., 2010) or actually decreased (Moisse et al., 2009) following injury to nerve cells.
Broadly, progranulin is anti-inflammatory whereas the granulin peptides are pro-inflammatory (Zhu et al., 2002) . The ability of progranulin to modulate inflammation in the periphery is well supported by results from Grn À/À knockout mice, which show normal immune development but a highly over-active inflammatory response to, for example, bacterial endotoxin (Yin et al., 2010a) . In general, progranulin appears to maintain inflammation within physiologically appropriate limits, and in its absence, a wide range of non-neuronal conditions with an inflammatory component exhibit a more severe phenotype (Liu, 2011; Wu and Siegel, 2011; Liu and Bosch, 2012; Miller et al., 2013) . There is strong evidence for a comparable influence of progranulin on neuroinflammation (Yin et al., 2010a; Martens et al., 2012 ) and as will be discussed below, there is growing evidence from animal models that disruption of neuroimmunomodulatory actions of progranulin are important in the development of FTLDrelated phenotypes.
In vitro and in vivo models to study GRN function
In vitro models of GRN function
Several in vitro models have been developed to investigate molecular mechanisms by which progranulin deficiency leads to neurodegeneration. These models demonstrated the ability of progranulin to promote neuronal survival, neurite outgrowth and neuronal morphology (Van Damme et al., 2008; Ryan et al., 2009; Gao et al., 2010; Kleinberger et al., 2010) . In primary murine hippocampal cultures, for example, progranulin deficiency decreased gross neural connectivity while enhancing transmission at individual synapses (Tapia et al., 2011) , possibly reflecting a compensatory mechanism resulting from a reduced number of synapses. A similar increase in the number of synaptic vesicles per synapse was also observed in tissues prepared from progranulin-associated FTLD patients (Tapia et al., 2011) . A member of the granulin peptide family, granulin-E, enhanced cell survival in cortical neurons and spinal cord motor neurons (Van Damme et al., 2008; Gass et al., 2012; De Muynck et al., 2013) , suggesting that both full-length progranulin and granulin peptides may possess neurotrophic functions. In contrast, other research suggests that granulin peptides may worsen TDP-43 pathologies (Salazar et al., 2015) . In a motor neuron-like cell line, stable overexpression of progranulin promoted cell survival for 2 months in the absence of serum in the culture medium whereas the control cells did not survive without serum beyond 2 weeks (Ryan et al., 2009) . The increased survival was associated with an inhibition of apoptosis. The powerful anti-apoptotic action of progranulin in neurons is amply confirmed by RNA silencing of progranulin expression in neuron cell cultures or cell lines and in cultured cortical neurons derived from Grn knockout mice, where, relative to control cells, caspase 3 activity is elevated in response to apoptotic stimuli Gao et al., 2010; Guo et al., 2010) . This may promote formation of carboxyl-terminal fragments (CTFs) of TDP-43 , although in cultured cortical neurons derived from Grn À/À mice the TDP-43 CTFs were reported to form both through caspase-dependent and independent pathways . Together these studies support the involvement of progranulin in neuronal survival through an anti-apoptotic pathway and that removal of progranulin regulation results in TDP-43 cleavage. It should be noted, however, that the influence of progranulin on caspase degradation of TDP-43 was not observed by others (Dormann et al., 2009) . In addition, amino-terminal sequencing indicated that the TDP-43 CTFs observed upon caspase cleavage are different from those isolated from the brains of FTLD patients (Igaz et al., 2009) . The mislocalization of TDP-43 from the nucleus to the cytoplasm is characteristic of FTLD. Neurons differentiated from induced pluripotent stem cells (iPSCs) obtained from FTLD patients (Almeida et al., 2012) or murine cortical cells depleted of progranulin by RNA silencing exhibited increased redistribution of TDP-43 to the cytoplasm from the nucleus. In the striatal cells from huntingtin (Htt) knock-in mice, progranulin protects against cell death whereas TDP-43 or FUS promotes cell death. Progranulin counteracts the effects of TDP-43 but not FUS in these cells (Tauffenberger et al., 2013) , supporting the concept of that progranulin is neuroprotective against TDP-43 abnormalities.
In vitro models utilizing progranulin depletion have provided some understanding of the biological functions of progranulin but cannot recapitulate all the pathologies associated with FTLD. To further characterize the roles of progranulin in FTLD pathology and widen understanding of the underlying mechanism of action of progranulin in vivo, various progranulin deficient animal models have been developed.
Worm models
Approximately 20% fewer progeny are observed in pgrn-1-deficient C. elegans mutants compared to wild-type (Kao et al., 2011) . These pgrn-1 deficient mutants showed increased clearance of apoptotic nerve cells suggesting that the precocious removal of nerve cells prevents the damaged or injured cells from recovering (Kao et al., 2011) . In a C. elegans model of neuronal TDP-43 proteinopathy, complete loss of the pgrn-1 gene, equivalent to NCL in humans, did not alter the severity of TDP-43 toxicity, but the loss of one copy of the pgrn-1 gene, as in FTLD, worsened TDP-43 toxicity. In addition, this study demonstrated a novel pathogenic role for granulin peptides in FTLD-TDP as motor impairments were significantly greater in a TDP-43 proteinopathy model co-expressing C. elegans granulin peptides than animals expressing either TDP-43 or granulin alone (Salazar et al., 2015) . Supporting this interpretation, the corresponding accumulation of granulin fragments in the diseased brain regions in human neurodegenerative disease subjects was also observed (Salazar et al., 2015) . In C. elegans, loss-of-function mutations of TDP-43 or FUS reduced behavioural defects and neurodegeneration caused by Htt exon-1 encoding an expanded polyglutamine tract implying roles for TDP-43 and FUS in huntingtin polyglutamine pathology. Progranulin attenuates the severity of this phenotype for TDP-43 but not FUS suggesting that TDP-43 acts upstream of progranulin (Tauffenberger et al., 2013) .
Zebrafish models
Unlike mammals that have only a single GRN gene, fish often have several distinct grn genes. Of the four grn genes in zebrafish, grna (encoding zfPGRN-A) is the true orthologue of the single human GRN gene (Cadieux et al., 2005) . Morpholino-based knockdown of zfPGRN-A resulted in truncated and inappropriate premature branching of developing primary motor neurons. In addition, overexpression of zfPGRN-A or human progranulin rescued truncation defects caused by the knockdown of zfPGRN-A (Chitramuthu et al., 2010) . The knockdown of zfPGRN-A causes greater reduction of motor neuron axonal length than the knockdown of zfPGRN-B (Laird et al., 2010) . Over-expressing progranulin rescued the axonopathy induced either by mutant TDP-43 or by a reduction in the expression of wild-type TDP-43 (Laird et al., 2010; Chitramuthu et al., 2017) as well as by the reduced expression of the smn1 causative gene for spinal muscular atrophy (Chitramuthu et al., 2010) . Another study reported that the knockdown of zfPGRN-A reduced the number of myogenic progenitor cells and impaired muscle growth , although a different study observed no such neuronal and muscle defects in a zinc finger nuclease (ZFN) derived grna À/À or grnb À/À models (Solchenberger et al., 2015) . The absence of neuronal and muscle defects in grn knockout models suggest the activation of compensatory mechanisms upon the complete loss of the grna and grnb gene (Solchenberger et al., 2015) compared to knockdown models. Other examples of genetic compensation in zebrafish gene knockout studies have been reported (Rossi et al., 2015) . Nerve cell independent roles of zfPGRN-A have been proposed in the control of liver size, hepatic proliferation and MET signalling in liver morphogenesis in zebrafish (Li et al., 2010) . There is no apparent NCL phenotype observed in grna À/À /grnb À/À double mutants in zebrafish (Solchenberger et al., 2015) but the short life-span of zebrafish may preclude the appearance of the NCL phenotype.
Mouse models: neuropathology, behaviour and neuroinflammation
Targeted overexpression of progranulin in peripheral and central neurons of mice promoted markedly faster axonal regrowth, reformation of neuromuscular junctions, reduction in recruitment of microglia to the site of injury and an improvement of motor functions after sciatic nerve injury compared to control mice (Altmann et al., 2016b) . Correspondingly, Grn À/À mice show significantly poorer recovery and greater inflammation than control mice (Altmann et al., 2016b) . Clearly, therefore, the specific neuronal over production of progranulin promotes neuronal recovery after injury.
Progranulin deficiency in mouse models produces abnormal neuronal and behavioural phenotypes. Abnormalities of Grn À/À mice include age-dependent neuronal ubiquitin accumulation, tissue vacuolation, microgliosis and astrogliosis, and selective neuronal loss (Ahmed et (Ahmed et al., 2010) . Patients carrying GRN mutations exhibit retinal thinning before the onset of dementia, and a similar retinal phenotype has been reported in Grn À/À mice associated with the loss of nuclear TDP-43 and cellular depletion of the GTPase, Ran (Ward et al., 2014) . Behavioural abnormalities of Grn-deficient mice include increased depression, disinhibition-like behaviour, together with deficiency in social recognition and spatial learning and memory, of which the most common behavioural phenotype is reduced social interaction (Yin et al., 2010b; Ghoshal et al., 2012; Petkau et al., 2012) . The behavioural phenotypes may be more severe in male animals (Kayasuga et al., 2007) possibly due to gender-specific differences in synaptic connectivity and impaired synaptic plasticity (Petkau et al., 2012) . The assessment of spatial memory functions by Morris water maze was less consistent between mouse models with reports ranging from reduced spatial memory (Yin et al., 2010b) to no difference in spatial memory (Petkau et al., 2012) . Defects in emotional behavioural and social recognition, synaptic transmission, and neuronal morphology occur before obvious signs of neuroinflammation (Yin et al., 2010b) or major neuropathological changes (Petkau et al., 2012) .
The absence of progranulin resulted in an apparent accelerated ageing of the brain as revealed by the significant increase with age in ubiquitin positive granular cytoplasmic staining and, importantly (Ahmed et al., 2010; Wils et al., 2012) extensive lipofuscinosis in the Grn knockout mice compared to age-matched wild-type control animals (Ahmed et al., 2010) . This is similar to observations in patients with GRN-related NCL (Smith et al., 2012) and may suggest that the Grn knockout mice are better models of NCL-11 than they are of FTLD. Clearly, NCL-11 and GRN-dependent FTLD are intimately related, but it remains uncertain at present to what extent they form a phenotypic continuum or are dissociable disease entities each with their own distinctive properties. With this caveat the relative paucity of strong FTLD-like phenotypes in the Grn À/À homozygotes, in particular with respect to the presence of ubiquitin TDP inclusions, may reflect the slow onset of disease in human patients, or suggest that additional factors, not yet well understood, are necessary to manifest a more robust FTLD-like phenotype. Interestingly it has been shown that the progranulin levels decrease with age in the cortex, hippocampus, and hypothalamus of wild-type mice suggesting that progranulin depletion may play a role in age-related decline in brain function.
Progranulin is highly upregulated in activated macrophages and microglia (Moisse et al., 2009; Philips et al., 2010; Tanaka et al., 2013a, b; Zhu et al., 2013) . In general, in Grn knockout mice there is increased expression of proinflammatory cytokines and exacerbated microglial activation and astrogliosis (Yin et al., 2010a, b; Ghoshal et al., 2012) . Macrophages and microglia from Grn À/À mice are cytotoxic to hippocampal cells in vitro (Yin et al., 2010a) , and show greater rates of phagocytotic apoptosis (Kao et al., 2011) . Progranulin deficiency increased microgliosis and the loss of dopaminergic neurons after toxin-induced injury caused by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydrophine (MPTP), a drug that specifically ablates dopaminergic neurons (Martens et al., 2012) . This was reproduced in mice in which Grn was conditionally knocked out only in microglia and macrophages strongly supporting the hypothesis that the susceptibility of Grn À/À mice to neurodegenerative processes results from a disruption in normal neuroinflammatory regulation (Martens et al., 2012) . Reducing microglial expression of progranulin in Alzheimer's disease mouse models increased their plaque burden and worsened cognitive deficits, demonstrating an essential role for microglial-derived progranulin in the clearance of aberrant amyloid-b deposits (Minami et al., 2014) . Progranulin deficiency leads to progressive upregulation of lysosomal and innate immunity genes, increased production of complement proteins and enhanced synaptic pruning by microglia in an age-dependent manner (Lui et al., 2016) . Indeed, in progranulin-deficient mice it has been proposed that aberrant microglial activation by complement proteins and the resultant increased synaptic pruning is a major cause, rather than a consequence, of neurodegeneration (Lui et al., 2016) .
Taken together these results support a role for progranulin in the CNS as a regulator of microglial activity, reducing their deleterious effects on neurons while enhancing their ability to remove amyloid plaques. Not all studies, however, are fully consistent with this conclusion. For example, both in vitro studies and lentiviral delivery of progranulin into mouse brains suggest that progranulin may be a chemoattractant for microglia (Pickford et al., 2011; Zhu et al., 2013) . In pilocarpine-induced epilepsy in mice, while progranulin was not required for microglial activation, it had potentiating activity (Zhu et al., 2013) . Depleting microglia of Grn mRNA by siRNA in vitro lowered rather than increased inflammatory cytokine production, leading to the conclusion that there is a stimulatory role for progranulin in microglial cytokine production (Suh et al., 2012) . Strongly pro-inflammatory stimuli such as lipopolysaccharide and polyIC (polyriboinosinic-polyribocytidilic acid) treatment inhibit microglial progranulin secretion in vitro (Suh et al., 2012) . In astroglia, however, which normally produce very little progranulin, polyIC has the opposite effect in that it stimulates progranulin secretion (Suh et al., 2012) . It is likely, therefore, that the inflammatory regulation of progranulin production in the CNS is cell-type specific.
Almost all studies that showed a strong neuroinflammatory phenotype were conducted in homozygous Grn À/À mice but in humans the loss of only a single allele of GRN is sufficient to cause FTLD. Rather mild phenotypes accrue in heterozygotic Grn + /À mice. Indeed, recent work suggests that the behavioural phenotypes of homozygous and heterozygous Grn knockout animals are distinct (Arrant et al., 2016) . Abnormalities of social and emotional behaviour, as well as changes in brain structure, particularly in the amygdala, occur in Grn + /À mice (Filiano et al., 2013) but this is independent of neuroinflammation or gliosis. Thus, structural and behavioural phenotypes can emerge in heterozygous Grn + /À mice, even in the absence of extensive microglial activation. In MPTP intoxicated mice (Martens et al., 2012 ) the loss of dopaminergic neurons in the substantia nigra follows an approximately linear relationship with respect to Grn allele number, falling by 66% in Grn À/À mice, by 50% in Grn + /À mice and 37% in wild-type mice. In contrast, excessive microglial neuroinflammation following MPTP treatment is markedly inflected with respect to Grn allele number, demonstrating a very strong 2.84-fold increase in the Grn À/À mice versus wild-type but a much smaller 1.33-fold increase in Grn + /À mice (Martens et al., 2012) . While the role of microglia in neuronal death in Grn À/À mice is well established, a question remains as to whether the rather marginal increase in the levels of microglia in the substantia nigra found in Grn + /À mice is sufficient by itself to cause the degree of dopaminergic neuronal loss that was observed. Given that: (i) behavioural phenotypes in Grn + /À mice can be dissociated from inflammation; (ii) progranulin influences neuronal survival in vitro independently of inflammatory stimuli; and (iii) that progranulin has actions in non-inflammatory C. elegans and zebrafish models (see above), it is reasonable to suppose that progranulin has a double-edged role in combating neurodegenerative disease, both by preventing the onset of a hostile neuroinflammatory microenvironment and supporting the survival of neurons in the face of injurious challenges.
Little is known about progranulin and neuroinflammation in humans with FTD and therefore how well the neuroinflammatory phenotypes of Grn À/À mice reproduce clinical FTD. Levels of IL6, but not TNF-, increase in the serum and CSF of carriers of GRN mutations once they become symptomatic (Bossu et al., 2011) . Postmortem brains of patients with FTLD-TDP43 caused by GRN mutations showed a clear, but limited increase in microglial number in the grey matter of the frontal cortex when compared to FTLD-TDP43 brains without GRN mutations. Microglial numbers were graded at 1.7 in GRN mutation carriers compared to 1.4 in FTD affected brains with normal GRN on a four-point scale of 0 to 3 (ChenPlotkin et al., 2010) . In GRN-related FTD, brain regions that were relatively unaffected showed a clear reduction in progranulin protein levels, whereas in the frontal and temporal cortices, no statistically significant decreases in progranulin were observed when compared to control samples, although a trend towards decreased progranulin can be discerned . Moreover, GRN mRNA was higher in the frontal cortex of GRN mutation carriers than it was in controls, a result clearly at variance with expectations based on GRN haploinsufficiency (ChenPlotkin et al., 2010) . The 'extra' GRN mRNA in frontal and temporal lobes was attributed to its production by microglia using the remaining functional GRN allele. Clearly, therefore, in the later stages of disease there is little if any deficit in microglial production of progranulin in regions of the brain with the most neuronal loss. Whether the microglial compensation of progranulin production occurs throughout disease progression is not known.
Mechanisms of action of progranulin
Progranulin interacts with many cellular processes, including lysosome function and autophagy, cellular localization of TDP-43, inflammation, cell survival, cell morphology, and cell signalling. Its actions appear to be mediated by binding to a range of different cell membrane proteins (Figs 4 and 5). Understanding how these diverse activities integrate at the cellular level will be essential to understand how progranulin deficiency causes neurodegeneration.
Progranulin and lysosomes
It is increasingly clear that protein degradation is compromised in FTLD (Gotzl et al., 2016) . Progranulin is involved in lysosome function and disruption of this function may be critical in the aetiology of GRN-related FTD. Homozygous loss of GRN in humans (Smith et al., 2012; Almeida et al., 2016) and mice (Ahmed et al., 2010) results in a profound disruption of lysosome function. The existence of ubiquitinated TDP-43 aggregates in GRN-related FTD implies a failure in protein clearance pathways. Furthermore, it is noteworthy that the genetic modifiers of GRN-related FTD, sortilin, TMEM106B and prosaposin all play roles in lysosomal function (Carrasquillo et al., 2010; Hu et al., 2010; Van Deerlin et al., 2010; Finch et al., 2011; Lang et al., 2012; Brady et al., 2013; Stagi et al., 2014; Zhou et al., 2015b) . In addition to binding progranulin (see above), sortilin is implicated in lysosomal trafficking of the acid sphingomyelinase and sphingolipid activator proteins (SAPs), which are necessary for the degradation of glycosphingolipids within lysosomes (Saftig and Klumperman, 2009) . Progranulin binds to prosaposin (Zhou et al., 2015b) , which is the precursor for SAPs suggesting a possible role for progranulin in this pathway (Fig. 4) . Progranulin deficiency results in an increase in TMEM106B in ageing mouse brains, while progranulin deficiency in neuronal TMEM106B transgenic mice significantly worsens lipofuscinosis (Zhou et al., 2017) . Interestingly, in humans, gene variants of TMEM106B and GRN are both associated with accelerated ageing in human brains (Rhinn and Abeliovich, 2017) suggesting a role for the progranulin/TMEMB106B pathway not only in FTD but also in healthy brain ageing. Autophagy is impaired in progranulin depleted neurons whereas in neuron-specific progranulin transgenic mice progranulin was found to interact with autophagy-related proteins, and proteins of the lysosome and endocytosis pathway (Altmann et al., 2016a) . This is consistent with reports from non-neuronal cells that also identified roles for progranulin in autophagy (Tian et al., 2016) . As the clearance of TDP-43 aggregates is mediated by autophagy (Scotter et al., 2014) , the depletion of progranulin in GRN-related FTD and the resultant impairment of autophagy may therefore favour the accumulation of TDP-43 aggregates, although this has yet to be formally proven. In a further link with the vesicular trafficking pathways, progranulin is involved in exosome signalling. Exosomes, which are secreted vesicles that are derived from endosomes, mediate important aspects of cell-cell communication. Not only is progranulin part of the cargo in human fibroblast exosomes but also, when progranulin content is depleted due to GRN mutation, the pattern of global exosome protein secretion was markedly altered (Benussi et al., 2016) supporting a role for progranulin in regulating exosome formation or secretion. Transcription factor EB (TFEB) has a central role in controlling lysosome biogenesis and when it is overexpressed in HeLa cells results in increased transcription of GRN mRNA (Belcastro et al., 2011) . The induction of lysosomes in HeLa cells by sucrose treatment elevated progranulin expression and correspondingly, the overexpression of progranulin resulted in increased lysosome size caused by a factor, most likely progranulin, secreted into the medium (Belcastro et al., 2011) . The brains of Grn À/À mice show enhanced expression of many lysosomal genes, as well as a higher proportion of microglia with nuclear TFEB, implying greater activation of the lysosome biogenesis pathways (Tanaka et al., 2013b) . When lysosome activity is sufficient to meet the needs of the cell, TFEB is retained in the cytosol through its phosphorylation by mammalian target of rapamycin (mTORC1) situated on the lysosomal membrane (Roczniak-Ferguson et al., 2012) . Loss of progranulin in Grn À/À mice appears to interfere with this process, releasing TFEB for translocation to the nucleus (Tanaka et al., 2013b) . Very high progranulin levels are found associated with amyloid plaques in Alzheimer's disease (Pereson et al., 2009) . The plaque-associated progranulin was found to be enriched in microglia in one study (Pereson et al., 2009 ), but in another study, it was associated with a subset of protease-depleted axonal lysosomes (Gowrishankar et al., 2015) reinforcing a probable connection between progranulin and lysosomal function.
TDP-43 and progranulin
Given that haploinsufficiency of GRN leads to TDP-43 proteinopathy, an appreciation of possible mechanisms that connect TDP-43 to neurodegeneration is clearly needed to understand the roles of progranulin in neuropathology. TDP-43 is an RNA-binding protein that is concentrated in the nucleus in healthy cells and consists of an N-terminal nuclear localization signal, two RNA recognition motifs and an extended glycine-rich carboxylterminal domain where pathogenic mutations cluster (reviewed in Cohen et al., 2011) . TDP43 plays roles in transcriptional regulation of RNA, RNA splicing, miRNA regulation, mRNA stabilization and mRNA transport (reviewed in Hanson et al., 2012) . Disruption of TDP-43-mediated RNA processing would, therefore, be likely to profoundly disrupt neuronal function, and there is considerable evidence for such loss of function mechanisms in TDP-43 neuropathology (Vanden Broeck et al., 2014) . Simply increasing TDP-43 levels in neuronal cells, however, results in a neurotoxic response Matsuoka, 2011, 2012; Yamashita et al., 2014; Suzuki et al., 2015) , which is consistent with a gain of toxic function and TDP-43 neurotoxicity may be, in fact, a complex interaction between both loss of function and gain of toxicity mechanisms (Cascella et al., 2016) . While disturbances of RNA processing are likely to be important in FTLD-TDP, whether progranulin interacts with these processes is not well understood. Depletion of progranulin in neurons results in mislocalization of TDP-43 from the nucleus to the cytoplasm Almeida et al., 2012) . The nuclear import of TDP-43 is regulated by the GTPase Ran, the levels of which are in turn regulated by TDP-43 (Ward et al., 2014) . In neurons that are deficient in progranulin, increasing the expression of Ran elevates nuclear TDP-43 levels and enhances cell survival (Ward et al., 2014) suggesting a functional linkage between progranulin depletion, Ran and the mislocation of TDP-43.
Progranulin signalling pathways
Progranulin activates both ERK1/2 (extracellular regulated kinase 1/2) and Akt signalling in many cell types (Zhou et al., 1993; Zanocco-Marani et al., 1999; Lu and Serrero, 2001; He et al., 2002; Kamrava et al., 2005; Monami et al., 2006; Guerra et al., 2007) including neurons Xu et al., 2011) . Neurons treated with progranulin showed enhanced phosphorylation of the serine/threonine kinase Akt and glycogen synthase kinase-3b (GSK-3b), a substrate of Akt, with subsequent inactivation of GSK-3b Nedachi et al., 2011) . Reduction of baseline levels of phospho-Akt were observed in Grn (2) Progranulin and prosaposin are secreted and sortilin is inserted into the cell membrane. (3) Binding of progranulin to sortilin facilitates the uptake of progranulin/sortilin to endosomes. Progranulin may also associate with prosaposin and be carried to endosomes as a passenger with prosaposin binding to the mannose-6-phosphate receptor (M6P) . The MR6P-mediated internalization of prosaposin/progranulin requires in addition lipoprotein receptor-related protein 1 (LRP1). (4) Progranulin is transferred to lysosomes, where it may be broken down by proteolysis to granulin peptides (small coloured dots). (5) In addition, sortilin and prosaposin may carry progranulin into lysosomes directly from the TGN Zhou et al., 2015b). completely abolished the neurotrophic effect of progranulin . Akt plays a role in pro-survival signalling pathways and transduces several functions including cell growth, apoptosis and survival among its many other activities (Song et al., 2005) . These results suggest a role for progranulin in mediating the Akt/GSK-3b pathway in neurite outgrowth and neuronal survival. In non-neuronal cells, progranulin signalling is associated with the activation of FAK (focal adhesion kinase) (He et al., 2002; Monami et al., 2006) . It is unknown whether progranulin similarly influences FAK activity in neurons.
There is increasing evidence that progranulin interacts with Wnt signalling. Thus, a functional genomic study in a human neural progenitor model of progranulin-deficiency and in FTD brains, identified apparently greater Wnt signalling as a result of progranulin deficiency (Rosen et al., 2011) . Wnt1 and progranulin expression are regulated reciprocally with progranulin increasing Wnt1 levels and vice versa (Wexler et al., 2011) . In lymphocytes from individuals carrying a loss-of-function GRN mutation, activation of non-canonical Wnt5a signalling was detected (Alquezar et al., 2014) . Aberrant activation of the Wnt signalling (Tang et al., 2011) . The arrow indicates activation and the blunt-ended line indicates inhibition. The question mark indicates that not all research groups detect progranulin binding to the TNFR Etemadi et al., 2013) . Progranulin is, in addition, a cofactor for CpG binding to toll-like receptor 9 either on cell membranes or in endocytotic vesicles (Park et al., 2011) . (B) Progranulin may influence non-inflammatory cell signalling through EphA receptors (Neill et al., 2016) or by notch signalling (Altmann et al., 2016b) . It is not yet clear whether progranulin forms a complex with the receptor and its typical ligand (ephrin or notch-ligand) or acts alone with these receptors. The bent red arrow indicates gene expression. CpG = unmethylated CpG; Eph A2 = Ephrin type-A receptor 2; Hes1 = hairy and enhancer of split-1; Hey1 = hairy/enhancer-of-split related with YRPW motif protein 1; IRFs = interferon-regulatory factors; MAPK = mitogenactivated protein kinase; MyD88 = myeloid differentiation primary response gene 88; NF-B = nuclear factor kappa-lightchain-enhancer of activated B cells; NICD = notchintracellular domain; TLR9 = Toll-like receptor 9; TNF = tumour necrosis factor; TNFR = TNF receptors.
pathway was also observed upon neuronal differentiation using iPSCs generated from patients with FTLD carrying a GRN null mutation (Raitano et al., 2015) . Both canonical and non-canonical Wnt signalling cascades were over-activated following GRN knockdown in SH-SY5Y neuroblastoma cells (de la Encarnacion et al., 2016) . As Wnt signalling may improve neuronal survival it is likely that its enhancement in GRN-related FTD acts as a protective adaptation to progranulin depletion (Rosen et al., 2011; Wexler et al., 2011) .
Progranulin receptors and binding proteins
No biologically active ligand functions in isolation but acts through its interaction with binding partners. With the exception of sortilin , little is known about progranulin binding proteins in the CNS. Notwithstanding this limitation, progranulin has been reported to bind to several proteins in the periphery although in many cases how some of these contribute to progranulin action remains to be fully determined. Progranulin binds to SLPI (Zhu et al., 2002) , as outlined earlier, and to several members of the matrix metalloproteinase family namely MMP2, MMP9, MMP13 and MMP14 and MMP17 (Liu et al., 2007; Butler et al., 2008; Suh et al., 2012) , and ADAMPTS-7 (a disintegrin and metalloproteinase with thrombospondin motifs 7) (Bai et al., 2009 ). In addition, it binds to the extracellular matrix proteins perlecan (Gonzalez et al., 2003) and cartilage oligomeric matrix protein . The association of progranulin with these extracellular matrix proteins may regulate its activity (Gonzalez et al., 2003; Xu et al., 2007; Bai et al., 2009) .
Membrane proteins that bind to progranulin (Figs 4 and 5) include sortilin , the tumour necrosis factor receptor (TNFR) (Tang et al., 2011) , the toll-like receptor 9 (TLR9) (Park et al., 2011) , Dlk (Baladron et al., 2002) , EphA2 (Chitramuthu and Bateman, 2016; Neill et al., 2016) and Notch receptors (Altmann et al., 2016b) . As noted above, sortilin regulates extracellular levels of progranulin (Carrasquillo et al., 2010; Hu et al., 2010) . Progranulin binds to the beta-propeller region of sortilin through its carboxyl-terminal tail (Zheng et al., 2011) . Progranulin is reported to act as a competitive antagonist of TNF-binding to the tumour necrosis factor type 1 and type 2 receptors (TNFR-I, TNFR-II) (Tang et al., 2011) . While this is consistent with the proposed role for progranulin in neuroinflammation, progranulin binding to TNFR has been challenged by other studies that found no progranulin binding to TNFRs Etemadi et al., 2013) . In addition, progranulin binds to both CpG ODNs and TLR9 acting as a soluble cofactor for TLR9 signalling (Park et al., 2011) thereby providing a further route through which progranulin might regulate inflammation and neuroinflammation (Aravalli et al., 2008; Scholtzova et al., 2014) .
Proteomic analysis of the prefontal cortex of mice engineered to specifically overexpress progranulin in neurons suggested a role for progranulin in Notch signalling (Altmann et al., 2016b) . Progranulin binds to all four Notch receptors through the Notch extracellular domain (Altmann et al., 2016b) . Others identified the tyrosine receptor kinase EphA2, an ephrin receptor, as a likely signalling partner for progranulin, although in this case in epithelial and endothelial cells (Neill et al., 2016) . It is noteworthy that both Notch and Ephrin signalling classically involve intimate cell-to-cell contact between a membrane-expressed ligand on one cell and the receptor on an immediately adjacent cell. Whether progranulin enters into the Notch-ligand/Notch or ephrin/EphA2 coupling, or instead binds Notch and EphA2 independently of their conventional partners is unknown (Chitramuthu and Bateman, 2016) . Defining the roles of these receptors in the neurobiology of progranulin is clearly an important goal.
Progranulin as the basis of potential therapeutics
Increasing the baseline expression of progranulin in GRNrelated FTD is a promising avenue for treatment, but, given the combined cytoprotective and immunomodulatory activities of progranulin, its use in other chronic neurodegenerative conditions or acute brain injury is also being explored. This is summarized in Fig. 6 and compared with similar strategies for the therapeutic use of progranulin in nonneuronal conditions.
Small molecule disease modifiers of GRN-related frontotemporal dementia
Current pharmacological treatment of FTD and related diseases are limited to providing relief for the behavioural, cognitive and motor symptoms of the disease (reviewed in Riedl et al., 2014) . There are no available therapies to stop or slow progression of the underlying neurodegeneration associated with FTLD (Riedl et al., 2014) . Of several recent or ongoing trials for potential FTD disease-modifying drugs listed in ClinicalTrails.gov (Tsai and Boxer, 2016) only two are targeted towards increasing brain progranulin levels or secretion, namely a phase 2 trial with the histone deacetylase (HDAC) inhibitor FRM-0334 (ClinicalTrials.gov Identifier: NCT02149160) and a phase 1 trial with the calcium channel blocker nimopidine, (ClinicalTrials.gov Identifier: NCT01835665) (Tsai and Boxer, 2016) . Results have not yet been reported from either trial.
HDAC inhibitors serve as drugs to treat cancer (Wang et al., 2005; Mottamal et al., 2015) . The HDAC inhibitor suberoylanilide hydroxamic acid (SAHA), also called vorinostat, was identified by chemical library screening to increase progranulin levels at both mRNA and protein levels and to reconstitute close to normal levels of progranulin in human GRN haploinsufficient cells in culture (Cenik et al., 2011) . SAHA does not easily cross the blood-brain barrier, but FRM-0334 does, stimulating investigation of its use as a potential progranulin-raising therapy (Tsai and Boxer, 2016) .
In an attempt to increase progranulin bioavailability, compounds were screened to determine if they might inhibit proteolytic degradation of progranulin (Capell et al., 2011) . While inhibitors of lysosomal proteases or inhibition of the ubiquitin proteasome system or inhibition of the neutrophil elastase, which cleaves progranulin into granulin peptides, had no effect on the amount of intracellular or secreted progranulin, the alkalizing reagent bafilomycinA1 (BafA1) significantly increased both intracellular as well as secreted progranulin levels (Capell et al., 2011) . Since vacuolar ATPase was identified as a target for BafA1, the properties of inhibitors of vacuolar ATPase such as concanamycin A, archazolid B and apicularen A were investigated and found to increase progranulin levels using both neuronal and nonneuronal cells including cultured primary cells derived from human patients with GRN loss-of-function mutations (Capell et al., 2011) . Amiodarone was one of the agents found to increase progranulin secretion through this mechanism, although preliminary trials of amiodarone treatment in patients did not demonstrate a clear therapeutic result (Alberici et al., 2014) .
Other groups have attempted to block the sortilin-progranulin axis with the goal of elevating progranulin levels . Sortilin peptide antagonists based structurally upon the carboxyl-terminal region of progranulin inhibit sortilin-mediated progranulin endocytosis and were found to restore extracellular progranulin in mammalian cell lines including patient-derived cell models as did a small molecule organic compound, 1-[2-(2-tert-butyl-5-methylphenoxy)-ethyl]-3-methylpiperidine, that specifically lowered sortilin levels . Prompted by the role of progranulin in lysosome biology, a cell-based screen of autophagy/lysosome modulators for molecules that regulate GRN promoter activity identified trehalose, an mTORindependent activator of autophagy (Holler et al., 2016) . Trehalose enhanced progranulin expression in iPSC-derived human neurons carrying a GRN mutation as well as in the brains of Grn haploinsufficient mice (Holler et al., 2016) . Trehalose has postulated therapeutic benefit in several neurodegenerative diaseases (Emanuele, 2014; Giorgetti et al., 2015; Li et al., 2015; Tanji et al., 2015; Tien et al., 2016) and is therefore a very promising lead in the search for new drugs to manage GRN-related FTD. Additional therapeutic targets are suggested by the discovery that receptor-interacting protein kinase 1 (RIPK1) regulates progranulin levels (Mason et al., 2017) . The strong inflammatory response to GRN depletion suggests that therapies that blunt overactive neuroinflammation may have potential benefit (Minami et al., 2015) .
GRN gene therapy in animal models of frontotemporal lobar degeneration, Parkinson's and Alzheimer's diseases Gene therapy may be an alternate strategy to increase brain progranulin levels. Viral delivery of progranulin to the medial prefrontal cortex of Grn + /À mice restored normal social dominance behaviour and normalized lysosomal abnormalities supporting a therapeutic potential for targeted progranulin treatment in FTD (Arrant et al., 2017) . Other animal models have focused on neurological diseases other than FTD. In a model of Parkinson's disease in mice, the lentiviral delivery of the GRN gene protected nigrostriatal neurons against the toxic effects of pretreatment with MPTP with the preservation of both dopamine content and locomotor function, as well as reduced expression of markers of inflammation and apoptosis (Van Kampen et al., 2014) . Another study demonstrated that lentiviral delivery of progranulin in a murine genetic model of Alzheimer's disease reduced plaque load, preserved hippocampal neurons and lowered memory deficits (Minami et al., 2015) . These results strongly suggest possible therapeutic avenues based on progranulin in many neurodegenerative pathologies in addition to FTD. Progranulin may potentially be used to treat multiple disease conditions including neurodegenerative diseases such as FTD, Alzheimer's disease (AD) and Parkinson's disease (PD) (Capell et al., 2011; Cenik et al., 2011; Van Kampen et al., 2014; Minami et al., 2015) acute brain injury (Tao et al., 2012; Egashira et al., 2013; Jackman et al., 2013; Kanazawa et al., 2015; Zhao and Bateman, 2015; Altmann et al., 2016b; Xie et al., 2016) , Targeted depletion of progranulin levels may be beneficial in treating gliomas (Bandey et al., 2015) . Progranulin has been suggested as a therapeutic target for many peripheral conditions particularly those with an important inflammatory component Sfikakis and Tsokos, 2011; Guo et al., 2012; Jian et al., 2013; Choi et al., 2014; Huang et al., 2015; Zhou et al., 2015a) .
Progranulin, a potential therapy in nerve injury and stroke
In addition to chronic neurodegenerative conditions, progranulin may have therapeutic properties in traumatic brain damage and peripheral nerve injury. Progranulin promotes the regrowth of injured sciatic nerves, suggesting that it may have benefits in the regeneration of damaged peripheral nerves (Altmann et al., 2016b) . Several studies using transgenic Grn mice or Grn knockout mice support a protective role for progranulin in stroke models (Tao et al., 2012; Egashira et al., 2013; Jackman et al., 2013; Kanazawa et al., 2015) . Lentiviral delivery of progranulin (Tao et al., 2012) , or intracerebroventricular delivery of recombinant progranulin 2 h following ischaemia (Egashira et al., 2013) or intraperitoneal injection of progranulin (Kanazawa et al., 2015) reduced infarct size, oedema, and mortality and enhanced neurological functions. Several mechanisms have been proposed for the protective action of progranulin in stroke models, including reduced reperfusion inflammation, cytoprotection of neurons, and effects on the integrity of the blood-brain barrier (Egashira et al., 2013; Jackman et al., 2013; Kanazawa et al., 2015) . Together these results suggest that progranulin has potential as an acute therapeutic treatment to improve stroke recovery.
Conclusion
Progranulin is a secreted protein whose reduced expression causes neurodegeneration. It has a multiplicity of targets regulating neuroinflammation, neuronal survival and neuronal cell structure. While much remains to discover with respect to its mode of action, an increased sensitivity of neurons to injury coupled to a more aggressive neuroinflammatory response is likely to account for the slow but relentless atrophy of key regions of the brain brought on by haploinsufficiency of GRN. That the complete deletion of the GRN results in lysosomal defects implies a hitherto unexpected but vital role for progranulin in the endocytosis-lysosomal pathway. Progranulin expression patterns, its molecular function and mechanism of action both in in vitro and in vivo models demonstrate the complexity of its effects. The potential therapeutic applications of progranulin in treating neurodegenerative diseases are enormous. Integrating the many facets of progranulin action, its roles as a neuroinflammatory modulator and a neurotrophic protein, as an extracellular regulatory signal and a protein involved in lysosomal function will be essential if the potential therapeutic applications of progranulin in treating various diseases are to be realized. 
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